SOTYKTU Market Summary

Key Factors Driving SOTYKTU Growth

1. First-in-class TYK2 inhibitor with differentiated mechanism

• SOTYKTU is the first and only selective TYK2 inhibitor, acting via allosteric inhibition rather than JAK blockade.
• This selectivity avoids many safety concerns seen with JAK inhibitors, improving physician confidence.

2. Strong and durable long-term efficacy (key clinical driver)

• Phase III + LTE data show:

o PASI 75 ~67–73% maintained up to 5 years

o PASI 90 ~46% at 5 years

• No new safety signals over >5,000 patient-years exposure

3. Large and underpenetrated psoriasis market

• Psoriasis affects ~100 million people globally
• Many patients remain undertreated or dissatisfied with current therapies

4. Oral convenience vs biologics (key commercial advantage)

• Once-daily oral dosing (vs injectable biologics like IL-17/IL-23 inhibitors)

Growth implication:

• Strong adoption in:

o Biologic-naïve patients

o Patients reluctant to use injections

• Drives earlier-line usage and broader prescribing base

5. Rapid label expansion into new indications

• FDA approval in psoriatic arthritis (2026)
• Ongoing development across multiple immune-mediated diseases (e.g., lupus, IBD – pipeline programs)

SOTYKTU Recent Developments

In March 2026, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) approved SOTYKTU (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).1 Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA.

“SOTYKTU Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SOTYKTU for approved indication like Plaque psoriasis; as well as potential indication like Juvenile rheumatoid arthritis, Psoriasis, Sjogren’s syndrome, Systemic lupus erythematosus, Alopecia areata, Crohn’s disease, Cutaneous lupus erythematosus, and Discoid lupus erythematosus in the 7MM. A detailed picture of SOTYKTU’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SOTYKTU for approved and potential indications. The SOTYKTU market report provides insights about SOTYKTU’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SOTYKTU performance, future market assessments inclusive of the SOTYKTU market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SOTYKTU sales forecasts, along with factors driving its market.

SOTYKTU Drug Summary

SOTYKTU (deucravacitinib) is an oral, first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb for the treatment of immune-mediated inflammatory diseases, primarily plaque psoriasis and more recently psoriatic arthritis. Administered as a once-daily oral tablet, SOTYKTU works intracellularly by binding to the regulatory domain of TYK2, leading to allosteric inhibition of the JAK-STAT signaling pathway and suppression of key pro-inflammatory cytokines such as IL-23, IL-17, and type I interferons that drive disease pathology. Its high selectivity for TYK2 distinguishes it from broader JAK inhibitors, potentially offering an improved safety profile while maintaining efficacy. Clinically, the drug has demonstrated significant reductions in psoriasis severity and inflammatory biomarkers, supporting its role as a targeted systemic therapy for patients who are candidates for systemic or phototherapy options. The report provides SOTYKTU’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SOTYKTU Market Report

The report provides insights into:

• A comprehensive product overview including the SOTYKTU MoA, description, dosage and administration, research and development activities in approved indications like Plaque psoriasis; as well as potential indication like Juvenile rheumatoid arthritis, Psoriasis, Sjogren’s syndrome, Systemic lupus erythematosus, Alopecia areata, Crohn’s disease, Cutaneous lupus erythematosus, and Discoid lupus erythematosus.
• Elaborated details on SOTYKTU regulatory milestones and other development activities have been provided in SOTYKTU market report.
• The report also highlights SOTYKTU‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The SOTYKTU market report also covers the patents information, generic entry and impact on cost cut.
• The SOTYKTU market report contains current and forecasted SOTYKTU sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SOTYKTU market report also features the SWOT analysis with analyst views for SOTYKTU in approved and potential indications.

Methodology

The SOTYKTU market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SOTYKTU Analytical Perspective by DelveInsight

• In-depth SOTYKTU Market Assessment

This SOTYKTU sales market forecast report provides a detailed market assessment of SOTYKTU for approved indication like Plaque psoriasis; as well as potential indication like Juvenile rheumatoid arthritis, Psoriasis, Sjogren’s syndrome, Systemic lupus erythematosus, Alopecia areata, Crohn’s disease, Cutaneous lupus erythematosus, and Discoid lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SOTYKTU sales data uptil 2034.

• SOTYKTU Clinical Assessment

The SOTYKTU market report provides the clinical trials information of SOTYKTU for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

SOTYKTU Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SOTYKTU Market Potential & Revenue Forecast

• Projected market size for the SOTYKTU and its key indications
• Estimated SOTYKTU sales potential (SOTYKTU peak sales forecasts)
• SOTYKTU Pricing strategies and reimbursement landscape

SOTYKTU Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SOTYKTU Market positioning compared to existing treatments
• SOTYKTU Strengths & weaknesses relative to competitors

SOTYKTU Regulatory & Commercial Milestones

• SOTYKTU Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SOTYKTU Clinical Differentiation

• SOTYKTU Efficacy & safety advantages over existing drugs
• SOTYKTU Unique selling points

SOTYKTU Market Report Highlights

• In the coming years, the SOTYKTU market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SOTYKTU companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SOTYKTU’s dominance.
• Other emerging products for Plaque psoriasis; as well as potential indication like Juvenile rheumatoid arthritis, Psoriasis, Sjogren’s syndrome, Systemic lupus erythematosus, Alopecia areata, Crohn’s disease, Cutaneous lupus erythematosus, and Discoid lupus erythematosus are expected to give tough market competition to SOTYKTU and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SOTYKTU in approved and potential indications.
• Analyse SOTYKTU cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SOTYKTU sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SOTYKTU in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SOTYKTU? How strong is SOTYKTU’s clinical and commercial performance?
• What is SOTYKTU’s clinical trial status in each individual indications such as Plaque psoriasis; as well as potential indication like Juvenile rheumatoid arthritis, Psoriasis, Sjogren’s syndrome, Systemic lupus erythematosus, Alopecia areata, Crohn’s disease, Cutaneous lupus erythematosus, and Discoid lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SOTYKTU Manufacturers?
• What are the key designations that have been granted to SOTYKTU for approved and potential indications? How are they going to impact SOTYKTU’s penetration in various geographies?
• What is the current and forecasted SOTYKTU market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SOTYKTU in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SOTYKTU for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is SOTYKTU? What is the duration of therapy and what are the geographical variations in cost per patient?